These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31019554)

  • 41. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
    Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB; Lakatos PL
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
    Martínez-Feito A; Bravo-Gallego LY; Hernández-Breijo B; Diez J; García-Ramirez L; Jaquotot M; Plasencia-Rodríguez C; Nozal P; Mezcua A; Martín-Arranz MD; Pascual-Salcedo D
    Sci Rep; 2020 Oct; 10(1):17099. PubMed ID: 33051546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world data on the infliximab biosimilar CT-P13 (Remsima
    Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM
    World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.
    Fischer S; Cohnen S; Klenske E; Schmitt H; Vitali F; Hirschmann S; Ramming A; Zundler S; Rath T; Krebs S; Dörje F; Uter W; Nagore D; Meyer S; Neurath MF; Atreya R
    Therap Adv Gastroenterol; 2021; 14():1756284820982802. PubMed ID: 33505519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.
    Dipasquale V; Cicala G; Spina E; Romano C
    Front Pharmacol; 2022; 13():846151. PubMed ID: 35370732
    [No Abstract]   [Full Text] [Related]  

  • 55. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
    Wook Hong S; Kim YG; Ye BD
    Immunotherapy; 2020 Jun; 12(9):609-623. PubMed ID: 32517574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.
    Jahnsen J
    Therap Adv Gastroenterol; 2016 May; 9(3):322-9. PubMed ID: 27134662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn's disease when switching from the original infliximab to its biosimilars].
    Knyazev OV; Zvyaglova MY; Kagramanova AV; Li IA; Sabelnikova EA; Lishchinskaya AA; Kulakov DS; Parfenov AI
    Ter Arkh; 2021 Feb; 93(2):150-157. PubMed ID: 36286628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
    Massimi D; Barberio B; Bertani L; Costa F; Ferronato A; Facchin S; Cardin R; Cingolani L; Casadei C; D'Incà R; Zingone F; Savarino EV
    Therap Adv Gastroenterol; 2021; 14():17562848211023384. PubMed ID: 34249147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L; Ilias A; Kurti Z; Lakatos PL
    Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.